Marc Hautot
Optometrist · Bogalusa, LANPI 1346215274
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $124 and has fallen 58.3% since, to $52 in 2025. That places this record below the midpoint for optometrist clinicians in LA, where the typical reported total is $1,075.
Across 29 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$128
- Alcon$83
- Bausch & Lomb, A Division Of Bausch Health US, LLC$75
- Sun Pharmaceutical Industries Inc.$70
- Bausch & Lomb Americas Inc.$61
- Apellis Pharmaceuticals, Inc.$52
- plus $140 from 5 others
What the payments were for
- Food & beverage$609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 6 | $128 |
| Alcon | 5 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $75 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Apellis Pharmaceuticals, Inc. | 1 | $52 |
| Aerie Pharmaceuticals, Inc. | 2 | $37 |
| Novartis | 2 | $35 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
How this compares
$609 in reported general payments places this provider in the 30th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 98 | $723 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $394 |
| Brimonidine Tartrate | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Bogalusa
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.